skin
-
Telormedix announces promising TMX-202 preclinical results for skin cancer treatment
Telormedix announced that it has achieved significant preclinical results for TMX-202, a compound developed for the safe and effective topical treatment of skin cancer. The recent preclinical study evaluated TMX-202 as a topical skin cancer treatment in a mouse skin cancer model and showed that it had both better efficacy and better tolerability than the current gold standard treatment for skin cancer, Imiquimod/Aldara.
skin | 15 November 2011
-
Telormedix announces promising TMX-202 preclinical results for skin cancer treatment
Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, announced that it has achieved significant preclinical results for TMX-202, a compound developed for the safe and effective topical treatment of skin cancer.
skin | 10 November 2011
-
Genentech to present progress in advanced skin, lung and ovarian cancer treatment
Genentech, a member of the Roche Group, announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the Amer…
skin | 19 May 2011
-
FDA approves Yervoy for the treatment of skin cancer patients
Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) approved Yervoy (ipilimumab) 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma. Yervoy is said to be the first and only th…
skin | 28 March 2011
-
Briakinumab achieves 75% skin clearance rates
In four separate pivotal clinical studies, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott 's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rat…
skin | 19 November 2010
-
Avita Medical to Distribute “Spray-On Skin†in Taiwan
Avita Medical has secured regulatory approval for its ReCell autologous spray-on skin from the Taiwan Ministry of Health. The target market for the product includes plastic and reconstructive surgeons, dermatologists, burns specialists and cosmeti…
skin | 22 April 2010
-
ReCell Receives FDA Approval for Clinical Trial
Avita Medical has received approval from the US Food and Drug Administration (FDA) to begin its US clinical trial for ReCell Spray-On Skin, a stand-alone regenerative point-of-care device enabling surgeons to treat burns, wounds and chronic skin defe…
skin | 25 December 2009
-
CHMP Delays Decision to Approve Zevtera
Janssen-Cilag has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has decided to delay the European Commission decision process on Zevtera (ceftobiprole medocaril) pending completion of a …
skin | 02 March 2009
-
Clinuvel: Interim Phase III Results for Skin Protection Drug
Melbourne-based Clinuvel Pharmaceuticals has announced interim results of its photoprotective drug, afamelanotide, in a Phase III trial conducted in Switzerland. The trial investigated the medical benefits of afamelanotide in the orphan disease e…
skin | 26 January 2009
-
Clinical Trial to Treat Rare Skin Disorder With siRNA Technology
PC Project, a public charity, announced that a Phase 1b clinical trial began today for treatment of pachyonychia congenita (PC) with a short interfering RNA (siRNA)-based therapeutic. PC is a dominant genetic disorder resulting from mutations in gene…
skin | 31 January 2008
